Now you can detect 50+ types of cancer with a simple blood draw1
Using cell-free DNA (cfDNA), the Galleri® test can detect cancer signals and predict the origin of the cancer signal with high accuracy.1 This revolutionary test will change the way we look at cancer, ushering in a new age of multi-cancer early detection while complementing guideline-recommended screening.

The future of multi-cancer early detection has arrived

Fighting cancer starts with knowing it’s there.

71%* of cancer deaths are caused by cancers without recommended screening.2,3

Potential to detect more cancers, early.

Using a multi-cancer early detection test alongside existing screening can help detect more cancers early.

One blood draw, detection of 50+ cancer types.1

When a cancer signal is detected, the test predicts the origin of the cancer signal with high accuracy.

*Data estimated for 2020 among individuals 50 – 79 years old. When calculated for 2021, 68% of cancer deaths are caused by cancers without recommended screening.

Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of Cancer Signal Not Detected” does not rule out cancer. A test result of Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. 

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory / test information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

Sign up for more information about the Galleri test

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167 – 1177. doi: 10.1016/j.annonc.2021.05.806.
  2. Modeled detection extrapolated to 2020 US population ages 50 – 79. Screening includes methods with United States Preventive Services Task Force (USPSTF) A, B, or C rating (breast, colon, cervical, prostate, and lung), and assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 33% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).
  3. Data on file from Surveillance, Epidemiology, and End Results (SEER) 18 Regs Research Data, Nov 2017 Submission. Includes persons aged 50 – 79. Estimated deaths per year in 2020 from American Cancer Society Cancer Facts and Figures 2020. Available at: www​.can​cer​.org/​c​o​n​t​e​n​t​/​d​a​m​/​c​a​n​c​e​r​-​o​r​g​/​r​e​s​e​a​r​c​h​/​c​a​n​c​e​r​-​f​a​c​t​s​-​a​n​d​-​s​t​a​t​i​s​t​i​c​s​/​a​n​n​u​a​l​-​c​a​n​c​e​r​-​f​a​c​t​s​-​a​n​d​-​f​i​g​u​r​e​s​/​2​0​2​0​/​c​a​n​c​e​r​-​f​a​c​t​s​-​a​n​d​-​f​i​g​u​r​e​s​-​2​0​2​0.pdf